Landmark study probes heart risks of Gender-Affirming hormones
NCT ID NCT07187947
Summary
This study aims to understand how gender-affirming hormone therapy (GAHT) affects heart health over time. It will follow 500 transgender adults who have been on hormone therapy for at least one year, tracking changes in blood pressure, cholesterol, body composition, and other health markers. The goal is to gather better evidence to help doctors monitor and manage potential cardiovascular risks for their patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIOVASCULAR (CV) RISK are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola
RECRUITINGBologna, BO, 40138, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.